Telix Pharmaceuticals Limited - Capital Markets Day - TELIX PHARMACEUTICALS LTD

Financial Performance:

• Revenue is projected to reach approximately $1 billion USD for the current year, expected to land at the top end of maintained guidance.
• The precision medicine business segment is forecast to grow >25% year-over-year, driven by a multi-product strategy and label expansions.
• The acquisition of ITM adds a recurring revenue stream with an 18% CAGR expected over the next five years, supported by a long-term contract for Lutetium-177 supply extending into the 2030s.
• Gross margins for the precision medicine business have improved to 65%, attributed to optimized distribution (RLS is now the second-largest distributor) and manufacturing control.
• ITM operates with 40% margins and is expected to generate $50 million in synergies within the first two years post-closing.
• The combined Telex-ITM entity is on a trajectory to reach $1.5 billion USD in revenue by the next year, with a strategic goal to transition to an earnings growth story by 2027-2028.
• Capital allocation is disciplined, funding R&D and infrastructure primarily through operating cash flow to minimize shareholder dilution.

Guidance and Future Outlook:

• 2027 is now projected as the primary commercial year for the combined entity, accelerated by the integration of ITM-11 and its therapeutic portfolio, moving the earnings inflection point forward from the original 2028 target.
• Long-term revenue potential is significant, with the isotope supply chain addressing 100+ drugs from 50+ companies, positioning Telex as a critical infrastructure partner.
• The company expects to have six FDA-approved products by this time next year, expanding from the current three, significantly multiplying revenue opportunities.
• Future growth is underpinned by the transition from diagnostic-focused revenue to a high-margin therapeutic model, leveraging a fully integrated "end-to-end" capability from isotope production to last-mile delivery.
• Management highlights a "multi-product, multi-jurisdictional" strategy to mitigate seasonality and market concentration risks, aiming for global patient access as a commercial standard.

Business Segments and Product Lines:

• Diagnostics (Precision Medicine):
  • Gazex (Gallium-68 PSMA): Commercially active in 22 countries; driving significant revenue growth and acting as a key platform for pipeline expansion.
  • PixClara (Fluciclovine): Recently FDA-approved for brain cancer imaging; expected to see rapid adoption following the FDA approval of the new indication for glioma.
  • Zircax (Zirconium-89 CA9): Anticipated FDA approval in 2027 for renal cell carcinoma (RCC) diagnosis, building on successful Phase 3 Zircon trial data.
  • Pax (Bypass): In late-stage development for pre-biopsy prostate cancer diagnosis; aims to triple the addressable patient volume by shifting imaging earlier in the diagnostic pathway.
• Therapeutics:
  • TLX591 (Antibody-Drug Conjugate): Phase 3 PROSEAC Global trial ongoing; a radiolabeled antibody for metastatic castration-resistant prostate cancer (mCRPC), showing durable retention and safety in combination with standard therapies.
  • TLX597 (Small Molecule): Next-generation PSMA radioligand; Phase 3 trials (OPTIMAL PSMA and OPTIMAL E) investigating dose intensification and dose adaptation in both late-line and early metastatic settings.
  • TLX101 (I-131): Investigational agent for glioblastoma (GBM); Phase 3 IPAX-BRIGHT (relapsed) and IPAX-T2 (upfront) trials showing stable disease and partial responses in preclinical/early data.
  • Luteon (Lu-177 Galectin-1): Phase 3 trial for metastatic clear cell renal cell carcinoma (ccRCC) targeting CA9 antigen; currently enrolling in Australia, Europe, and the US.
• Isotope Supply Chain (ITM Integration):
  • ITM produces ~80% of the world's Lutetium-177 and is expanding production of Actinium-225, Lead-212, and Terbium isotopes.
  • New infrastructure includes a commercial Actinium-225 facility under construction in Philadelphia and expanded Gallium-68 cyclotron capacity.

Market and Competitive Landscape:

• The radiopharmaceutical market is pivoting rapidly from diagnostics (5% CAGR) to therapeutics, a sector expected to drive the next decade of growth.
• Infrastructure is the key competitive moat: Most competitors rely on third-party manufacturers; Telex controls 45 global manufacturing sites, ensuring supply security and speed-to-market (e.g., PIX-Clar launch was 2 weeks vs. 4 months for historical launches).
• The competitive race involves both pipeline development and commercial supply chain ownership; Telex argues that without controlling the "last mile" (distribution and isotopes), companies risk missed doses and lost clinical relationships.
• Telex differentiates itself as a vertically integrated biopharma rather than a pure-play CDMO, allowing it to serve as a partner for Big Pharma and other biotechs needing commercial execution and supply reliability.
• Key Opinion Leaders (KOLs) cited the shift from "blind biopsies" to PSMA PET-guided diagnosis as a paradigm shift that reduces unnecessary procedures and improves patient outcomes.

Risks and Challenges:

• Supply Chain Complexity: Manufacturing radiopharmaceuticals requires highly specialized infrastructure (cyclotrons, reactors) with limited global availability; scaling production is technically difficult and capital intensive.
• Regulatory Uncertainty: Delays in FDA approvals (e.g., Zircax) and the evolving regulatory landscape for biologics vs. small molecules in radiopharma present execution risks.
• Clinical Execution: Success relies on complex Phase 3 trials and the ability to secure patient enrollment for rare diseases (e.g., glioblastoma).
• Market Adoption: Shifting clinical practice guidelines (e.g., moving PSMA PET to pre-biopsy settings) requires convincing payers and practitioners of the value proposition over standard of care.
• Competition: Intense competition for isotope supply and commercial shelf space as 50+ companies enter the therapeutic radiopharma space.

Management Commentary and Tone:

• Confident and Strategic: Management projects a "global radiopharma powerhouse" vision, emphasizing that the company has successfully navigated the transition from a diagnostic-focused biotech to a commercial therapeutic leader.
• Disciplined Capital Allocation: CFO Darren Smith emphasized a self-funding model where precision medicine profits reinvest into the therapeutic pipeline and supply chain, avoiding excessive dilution.
• Vertical Integration as a Moat: CEO Chris Barron-Brooks repeatedly stressed that supply chain control is not just operational but a strategic imperative for clinical outcomes and margin protection.
• Patient-Centric Focus: Strong emphasis on treating the "entire prostate cancer continuum" and addressing "drug development deserts" like glioblastoma.
• Tone: Optimistic about the near-term catalysts (2027 readouts) but realistic about the long-term nature of building a fully integrated global business.

Analyst Questions and Answers:

• Gallium vs. Fluorine-18: KOLs confirmed Gallium-68 offers superior specificity and lower false positives in bone (due to liver shunting of free Gallium vs. bone shunting of Fluorine), justifying its dominance despite Fluorine-18's convenience; early imaging with Gallium is shown to be superior to 24-hour Copper-64 scans.
• Bypass Trial Impact: Questions focused on how pre-biopsy imaging will alter the $670k current TAM; management expects a massive shift where 821k scans/year could be performed upfront, reducing downstream biopsies and recurrence monitoring.
• 597 Dosing Strategy: Discussion on Optimal PSMA trial revealed that dose intensification (3 doses in 2 weeks) is feasible and safe with 597, allowing for higher biological effective doses to tumors while maintaining low kidney/salivary toxicity due to the molecule's clean clearance.
• Biologics vs. Small Molecules: Management remains agnostic; however, biologics (TLX591) offer longer tumor retention, while small molecules (TLX597) offer faster clearance and lower off-target uptake. The choice depends on the therapeutic need (e.g., alpha emitters may benefit from antibodies).
• ITM Synergies: Confirmed $50M synergies expected within 2 years, primarily through shared supply chain costs and the ability to commercialize ITM's isotope portfolio alongside Telex's drugs.
• Kidney Cancer Pipeline: CA9 targeting (Zircax/Luteon) is validated as a "beautiful target" (Specific, Prevalent, High Expression) with high uptake in clear cell RCC, differentiating from other potential targets.

Other Key Points:

• KOL Presentations: Four external KOLs (Profs. Ghassani, Dundee, Emmett, Scott) provided critical clinical validation for PSMA imaging in prostate cancer, FET-PET in brain cancer, and the potential of CA9 imaging in kidney cancer.
• Strategic Pivot: The company has moved from a "small biopharma" model to a "global powerhouse" by acquiring ITM-11, which brings essential isotope manufacturing capabilities and a therapeutic pipeline (ITM-11).
• Regulatory Milestones: Upcoming FDA decisions on Zircax (2027) and readouts for TLX597 (Optimal PSMA) and TLX101 (IPAX-BRIGHT) are identified as key catalysts for 2026-2027.
• Global Expansion: Telex is actively commercializing in 22 countries and expanding into EMEA, aiming for a truly global footprint rather than focusing solely on the US.
• Compassionate Use: High demand for TLX101 in glioblastoma patients outside trials has led to the establishment of a compassionate use program, highlighting the unmet medical need.
• Infrastructure Investment: Over $100 million annual investment is planned for continued infrastructure growth (cyclotrons, GMP sites) to maintain the competitive moat.